DC Funds’s TScan Therapeutics TCRX Stock Holding History

DC Funds’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$617K	Hold	630,000	–	–	49.27%	1
2026 Q1	$630K	Hold	630,000	–	–	42.4%	1
2025 Q4	$630K	Hold	630,000	–	–	43.36%	1
2025 Q3	$1.15M	Hold	630,000	–	–	36.87%	2
2025 Q2	$914K	Hold	630,000	–	–	42.43%	1
2025 Q1	$869K	Hold	630,000	–	–	42.07%	1
2024 Q4	$1.92M	Hold	630,000	–	–	53.75%	1
2024 Q3	$3.14M	Hold	630,000	–	–	60.91%	1
2024 Q2	$3.69M	Hold	630,000	–	–	61.2%	1
2024 Q1	$5M	Hold	630,000	–	–	48.34%	1
2023 Q4	$3.67M	Hold	630,000	–	–	44.16%	1
2023 Q3	$1.61M	Hold	630,000	–	–	33.2%	2
2023 Q2	$1.57M	Hold	630,000	–	–	33.55%	2
2023 Q1	$1.32M	Hold	630,000	–	–	30.82%	3
2022 Q4	$977K	Hold	630,000	–	–	26.44%	3
2022 Q3	$1.92M	Hold	630,000	–	–	28.97%	3
2022 Q2	$1.98M	Hold	630,000	–	–	27.33%	3
2022 Q1	$1.76M	Hold	630,000	–	–	22.92%	3
2021 Q4	$2.83M	Hold	630,000	–	–	16.79%	3
2021 Q3	$5.25M	Buy	+630,000	New	+$5.84M	20.63%	3

Other funds holding TCRX

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

DC Funds's TCRX Position: Q2 2026 in Review

DC Funds held its TScan Therapeutics (TCRX) position steady in Q2 2026 at 630,000 shares worth $617K. The position accounts for 49.27% of the portfolio, ranked #1.

DC Funds first reported a position in TCRX in Q3 2021 and has held it in 20 quarters since. The position peaked at $5.25M in Q3 2021. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

DC Funds held 630,000 shares of TScan Therapeutics worth $617K as of Q2 2026.
DC Funds left its TScan Therapeutics share count unchanged in Q2 2026.
TScan Therapeutics made up 49.27% of DC Funds's portfolio in Q2 2026, its #1 holding.
DC Funds first reported a position in TScan Therapeutics in Q3 2021 and has held it in 20 quarters since.
DC Funds's TScan Therapeutics position peaked at $5.25M in Q3 2021.
60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on DC Funds's 13F filing for Q2 2026, filed 14 Aug 2026.